Akari Therapeutics (AKTX) Gains from Investment Securities (2015 - 2026)
Akari Therapeutics recorded quarterly Gains from Investment Securities of $8750.0 in Q1 2026, down 94.86% quarter-over-quarter from $170137.0 in Q4 2025, and down 98.91% year-over-year from $800000.0 in Q1 2025.
Akari Therapeutics' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $8750.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 98.91% year-over-year to $8750.0; the TTM figure through Mar 2026 stood at $8750.0 (down 98.91% YoY), while the FY2025 annual figure was $170137.0, down 97.23% from the prior year.
- Gains from Investment Securities came in at $8750.0 for Q1 2026 at Akari Therapeutics, down from $170137.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $19.2 billion in Q2 2025 to a low of -$120.5 million in Q2 2024.
- A 5-year average of $1.8 billion and a median of $1.4 million in 2023 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities slumped 114.08% in 2024 and surged 50068.51% in 2025, its largest moves.
- Akari Therapeutics' Gains from Investment Securities stood at $513.7 million in 2022, then slumped by 99.61% to $2.0 million in 2023, then soared by 209.84% to $6.1 million in 2024, then plunged by 97.23% to $170137.0 in 2025, then slumped by 94.86% to $8750.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $8750.0, $170137.0, and $587130.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,750.00 |
| Mar 31, 2026 | 8,750.00 |
| Dec 31, 2025 | 104,896.00 |
| Dec 31, 2025 | 104,896.00 |
| Sep 30, 2025 | 7.42 Bn |
| Sep 30, 2025 | 7.42 Bn |
| Jun 30, 2025 | 19.17 Bn |
| Jun 30, 2025 | 19.17 Bn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 6.81 Bn |
| Dec 31, 2024 | 6.81 Bn |
| Sep 30, 2024 | -1,175.00 |
| Sep 30, 2024 | -1,175.00 |
| Jun 30, 2024 | -120.49 Mn |
| Jun 30, 2024 | -120.49 Mn |
| Mar 31, 2024 | 626.74 Mn |
| Mar 31, 2024 | 626.74 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Jun 30, 2023 | 855.64 Mn |
| Jun 30, 2023 | 855.64 Mn |
| Dec 31, 2022 | 513.67 Mn |
| Dec 31, 2022 | 513.67 Mn |
| Dec 31, 2021 | 142.95 Mn |
| Dec 31, 2021 | 142.95 Mn |
| Dec 31, 2019 | 94.35 Mn |
| Dec 31, 2019 | 94.35 Mn |
| Dec 31, 2018 | 94.10 Mn |
| Dec 31, 2018 | 94.10 Mn |
| Dec 31, 2017 | 90.06 Mn |
| Dec 31, 2017 | 90.06 Mn |
| Dec 31, 2016 | 79.37 Mn |
| Dec 31, 2016 | 79.37 Mn |
| Dec 31, 2015 | -10.77 Mn |
| Dec 31, 2015 | -10.77 Mn |